Francois Bretin
Aventis Pharma
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Francois Bretin.
Bioorganic & Medicinal Chemistry Letters | 1999
Alexis Denis; Constantin Agouridas; Jean-Michel Auger; Yannick Benedetti; Alain Bonnefoy; Francois Bretin; Jean-Francois Chantot; Arlette Dussarat; Claude Fromentin; Solange Gouin d'Ambrieres; Sylvette Lachaud; Patrick Laurin; Odile Le Martret; Véronique Loyau; Nicole Tessot; Jean-Marie Pejac; Sébastien Perron
In the search for new ketolides with improved activities against erythromycin-resistant S. pneumoniae and H. influenzae we synthesized a new 11,12 carbamate ketolide substituted by an imidazo-pyridyl side chain: HMR 3647. This compound demonstrated a potent activity against erythromycin susceptible and resistant pathogens, including penicillin G/erythromycin A-resistant S. pneumoniae and H. influenzae. In vivo, HMR 3647 displayed good pharmacokinetic parameters (Cmax = 2.9 microg/ml, bioavailability=49%, AUC0.8 = 17.2 microg.h/l, t1/2=1h) and was shown to have a high therapeutic efficacy in mice infected by various respiratory pathogens, including multi-resistant S. pneumoniae and Gram negative bacteria such as H. influenzae. HMR 3647 appears to be a very promising agent for the treatment of respiratory infections and is currently in clinical trials.
Bioorganic & Medicinal Chemistry Letters | 2000
Alexis Denis; Francois Bretin; Claude Fromentin; A Bonnet; Alain Bonnefoy; Constantin Agouridas; G Piltan
The effect of 2,3 modifications on the antibacterial activity of ketolides was evaluated by introducing substituents in position 2 and converting the C-1, C-2, C-3 beta-keto-ester into stable 2,3 enol-ether or 2,3 anhydro derivatives. Introduction of a fluorine in C-2 is beneficial with regard to the overall antibacterial spectrum whereas the enol-ether and 2,3 unsaturated compounds, as well as the bulky gem dimethyl or 2-chloro derivatives, are less active particularly against erythromycin resistant strains. A 2-fluoro ketolide derivative demonstrates good antibacterial activity and in vivo efficacy against multi-resistant Streptococcus pneumoniae. Compared to azithromycin against Haemophilus influenzae, this compound is equivalent in vitro and slightly more active in vivo. These results demonstrate that within the ketolide class, to retain good antibacterial activity, position 2 needs to remain tetrahedral and tolerates only very small substituents such as fluorine.
Bioorganic & Medicinal Chemistry | 2003
Alexis Denis; Jean-Marie Pejac; Francois Bretin; Alain Bonnefoy
A series of 9-oxime-11,12-carbamate ketolides was synthesized for the first time through a key 11,12-hydrazonocarbamate intermediate that was first oximated and further deaminated to give the corresponding carbamate. The N-N bond cleavage was achieved through an original new reaction using glycoaldehyde dimer as deaminating reagent. The new compounds synthesized were shown to display improved antibacterial activities against Streptococcus pneumoniae and S. pyogenes resistant to erythromycin.
Journal of Medicinal Chemistry | 1998
Constantin Agouridas; Alexis Denis; Jean-Michel Auger; Yannick Benedetti; Alain Bonnefoy; Francois Bretin; Jean-Francois Chantot; Arlette Dussarat; Claude Fromentin; Solange Gouin d'Ambrieres; Sylvette Lachaud; Patrick Laurin; Odile Le Martret; and Véronique Loyau; Nicole Tessot
Archive | 1996
Constantin Agouridas; Francois Bretin; Jean-Francois Chantot
Archive | 2002
Constantin Agouridas; Francois Bretin; Alexis Denis; Claude Fromentin
Archive | 1995
Constantin Agouridas; Francois Bretin; Jean Francois Chantot
Archive | 1999
Constantin Agouridas; Francois Bretin; Alexis Denis; Claude Fromentin
Archive | 1999
Constantin Agouridas; Francois Bretin; Alexis Denis; Claude Fromentin; アレクシー・ドニ; クロード・フロマンタン; コンスタンタン・アグリーダ; フランソワ・ブルタン
Archive | 1999
Constantin Agouridas; Alexis Denis; Francois Bretin; Claude Fromentin